Edition:
United Kingdom

Deena Beasley

Novartis bietet US-Krankenversicherern Rabatt für teure Gentherapie

13 May 2019

Zürich/Los Angeles Der Schweizer Pharmakonzern Novartis bietet Krankenversicherungen in den USA Preisnachlässe für seine neue Gentherapie gegen die Muskelerkrankung SMA.

Exclusive: Novartis pitches discounts on pricey gene therapy for deadly muscle disorder

10 May 2019

LOS ANGELES/ZURICH Novartis AG is offering price discounts in negotiations with U.S. health insurers on its gene therapy for spinal muscular atrophy (SMA), a treatment that could cost more than a million dollars, but the gesture comes with strings attached.

Gilead to separate Kite cell therapy unit, posts higher profit

02 May 2019

Gilead Sciences Inc, which hired Roche veteran Daniel O'Day to be its new chief executive, on Thursday said Kite Pharma, the cancer-focused cell therapy company it acquired in 2017, will become a separate business unit.

Gilead posts higher first-quarter profit; drug sales in line with expectations

02 May 2019

May 2 Gilead Sciences Inc on Thursday reported a higher first-quarter profit as sales of its important HIV and hepatitis C drugs were largely in line with Wall Street estimates.

Amgen revenue flat as migraine, cholesterol drugs miss sales expectations

01 May 2019

Amgen Inc on Tuesday reported first-quarter revenue that was unchanged from a year ago as key drugs, including new migraine treatment Aimovig and cholesterol fighter Repatha, face pricing pressure.

Amgen revenue flat for first quarter, Aimovig, Repatha fall short of sales expectations

30 Apr 2019

April 30 Amgen Inc on Tuesday reported first-quarter revenue that was unchanged from a year ago and net income fell 14 percent as sales of key drugs, including new migraine treatment Aimovig and cholesterol fighter Repatha, face competition and pressure to lower prices.

Medicare offers to partially raise payment for cancer CAR-Ts

23 Apr 2019

The U.S. Centers for Medicare and Medicaid Services will slightly increase coverage for expensive CAR-T cell therapies administered at certain large hospitals, and is considering other ways to pay more for the cancer treatments, the agency said on Tuesday.

Second death in Novartis gene therapy trials under investigation

20 Apr 2019

Novartis AG, which this week announced positive interim trial results for its experimental gene therapy for spinal muscular atrophy, on Friday said investigation is underway into whether a second trial death could be related to the treatment.

Amgen sets $21,900 annual price for new Evenity bone drug

15 Apr 2019

Amgen Inc on Monday set the U.S. list price for its new Evenity osteoporosis drug at $1,825 a month, or $21,900 for a full 12-month course of injections.

Novartis, Amgen in dispute over migraine drug partnership

04 Apr 2019

NEW YORK/LOS ANGELES Swiss drugmaker Novartis AG sued Amgen Inc on Thursday, accusing the U.S. biotechnology company of trying to wrongfully back out of agreements to jointly develop and market the migraine prevention drug Aimovig and keep the profits for itself.

World News